GENE ONLINE|News &
FDA approves Eli Lilly’s oral obesity drug Foundayo as an alternative to injections
The U.S. Food and Drug Administration has approved a new oral medication for obesity developed by Eli Lilly, marking a significant addition to the range of treatment options available for weight management. The drug, named Foundayo, provides an alternative to injectable medications currently used in similar treatments.
Foundayo is designed to offer convenience for patients who prefer not to use injections as part of their therapy. Eli Lilly’s development of this pill represents an effort to address patient preferences while maintaining efficacy in managing obesity. The approval follows clinical trials that evaluated the drug’s safety and effectiveness, though specific details regarding trial outcomes were not disclosed in the announcement.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: April 1, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Study Finds Non-Communicable Diseases Consume Large Portion of Household Income Among Elderly in India
2026-04-19
Study Identifies Antiviral Compounds in Egyptian Ziziphus spina-christi Effective Against Respiratory Viruses
2026-04-19
Elevated Fetal Catecholamine Metabolites Linked to Growth Restriction in Sheep Model Study
2026-04-18
EVENT
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
